Limits...
Ganoderma lucidum inhibits proliferation of human ovarian cancer cells by suppressing VEGF expression and up-regulating the expression of connexin 43.

Dai S, Liu J, Sun X, Wang N - BMC Complement Altern Med (2014)

Bottom Line: Ganoderma lucidum (G. lucidum, Reishimax) is an herbal mushroom known to have inhibitory effect on tumor cell growth.G. lucidum treatment resulted in reduced proliferation of HOCC.Furthermore, knockdown of Cx43 expression in HOCC abrogated the effect of G. lucidum on cell proliferation without alteration of G. lucidum-induced attenuation of VEGF expression.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, The Affiliated Shengjing Hospital, China Medical University, 36 Sanhao Street, Heping district, Shenyang 110004, People's Republic of China. daishy2014@163.com.

ABSTRACT

Background: Ganoderma lucidum (G. lucidum, Reishimax) is an herbal mushroom known to have inhibitory effect on tumor cell growth. However, the molecular mechanisms responsible for its anti-proliferative effects on the ovarian cancer have not been fully elucidated.

Methods: Human ovarian cancer cells HO 8910 (HOCC) and human primary ovarian cells (HPOC) were treated with G. lucidum. Effects of G. lucidum treatment on cell proliferation were studied by MTT assay. The expression of vascular endothelial growth factor (VEGF) and connexin 43 (Cx43) were measured by immunohistochemistry and real time polymerase chain reaction. To study the molecular mechanism of CX43 mediated anti-tumor activity, small interference RNA (siRNA) was used to knockdown Cx43 expression in HOCC.

Results: G. lucidum treatment resulted in reduced proliferation of HOCC. Inhibition of proliferation was accompanied by a decrease in VEGF expression and increase in Cx43 expression in the cancer cells. The extent of immune-reactivity of Cx43 or VEGF in cancer cells were correlated with the concentrations of G. lucidum used for treatment. Furthermore, knockdown of Cx43 expression in HOCC abrogated the effect of G. lucidum on cell proliferation without alteration of G. lucidum-induced attenuation of VEGF expression.

Conclusions: G. lucidum inhibits ovarian cancer by down-regulating the expression of VEGF and up-regulating the downstream Cx43 expression. G. lucidum may be a promising therapeutic agent for the treatment of ovarian cancer.

Show MeSH

Related in: MedlinePlus

Quantitative comparison of protein levels for Cx43 and VEGF in HOCC and HPOC treated with or withoutG. lucidum. Data are shown as mean ± S.D. of three independent experiments. *P < 0.05 vs respective day 0; †P < 0.05 vs corresponding untreated group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4232730&req=5

Fig4: Quantitative comparison of protein levels for Cx43 and VEGF in HOCC and HPOC treated with or withoutG. lucidum. Data are shown as mean ± S.D. of three independent experiments. *P < 0.05 vs respective day 0; †P < 0.05 vs corresponding untreated group.

Mentions: In untreated groups, the expression of Cx43 protein increased in HPOC, whereas it decreased in HOCC during 3 days of culture (Figures 3 and4). The VEGF protein expression increased in both HPOC and HOCC at day 3. In treated group, the Cx43 protein expression was significantly augmented in both HPOC and HOCC at day 3. The increase in Cx43 protein expression was more pronounced in HOCC compared with HPOC. As expected, the VEGF protein expression was efficiently suppressed in both HOCC and HPOC treated with G lucidum. Thus, these results are consistent with mRNA data from our study and other report in the ovarian cancer cell[14], suggesting that HOCC are sensitive to G. lucidum treatment.Figure 3


Ganoderma lucidum inhibits proliferation of human ovarian cancer cells by suppressing VEGF expression and up-regulating the expression of connexin 43.

Dai S, Liu J, Sun X, Wang N - BMC Complement Altern Med (2014)

Quantitative comparison of protein levels for Cx43 and VEGF in HOCC and HPOC treated with or withoutG. lucidum. Data are shown as mean ± S.D. of three independent experiments. *P < 0.05 vs respective day 0; †P < 0.05 vs corresponding untreated group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4232730&req=5

Fig4: Quantitative comparison of protein levels for Cx43 and VEGF in HOCC and HPOC treated with or withoutG. lucidum. Data are shown as mean ± S.D. of three independent experiments. *P < 0.05 vs respective day 0; †P < 0.05 vs corresponding untreated group.
Mentions: In untreated groups, the expression of Cx43 protein increased in HPOC, whereas it decreased in HOCC during 3 days of culture (Figures 3 and4). The VEGF protein expression increased in both HPOC and HOCC at day 3. In treated group, the Cx43 protein expression was significantly augmented in both HPOC and HOCC at day 3. The increase in Cx43 protein expression was more pronounced in HOCC compared with HPOC. As expected, the VEGF protein expression was efficiently suppressed in both HOCC and HPOC treated with G lucidum. Thus, these results are consistent with mRNA data from our study and other report in the ovarian cancer cell[14], suggesting that HOCC are sensitive to G. lucidum treatment.Figure 3

Bottom Line: Ganoderma lucidum (G. lucidum, Reishimax) is an herbal mushroom known to have inhibitory effect on tumor cell growth.G. lucidum treatment resulted in reduced proliferation of HOCC.Furthermore, knockdown of Cx43 expression in HOCC abrogated the effect of G. lucidum on cell proliferation without alteration of G. lucidum-induced attenuation of VEGF expression.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, The Affiliated Shengjing Hospital, China Medical University, 36 Sanhao Street, Heping district, Shenyang 110004, People's Republic of China. daishy2014@163.com.

ABSTRACT

Background: Ganoderma lucidum (G. lucidum, Reishimax) is an herbal mushroom known to have inhibitory effect on tumor cell growth. However, the molecular mechanisms responsible for its anti-proliferative effects on the ovarian cancer have not been fully elucidated.

Methods: Human ovarian cancer cells HO 8910 (HOCC) and human primary ovarian cells (HPOC) were treated with G. lucidum. Effects of G. lucidum treatment on cell proliferation were studied by MTT assay. The expression of vascular endothelial growth factor (VEGF) and connexin 43 (Cx43) were measured by immunohistochemistry and real time polymerase chain reaction. To study the molecular mechanism of CX43 mediated anti-tumor activity, small interference RNA (siRNA) was used to knockdown Cx43 expression in HOCC.

Results: G. lucidum treatment resulted in reduced proliferation of HOCC. Inhibition of proliferation was accompanied by a decrease in VEGF expression and increase in Cx43 expression in the cancer cells. The extent of immune-reactivity of Cx43 or VEGF in cancer cells were correlated with the concentrations of G. lucidum used for treatment. Furthermore, knockdown of Cx43 expression in HOCC abrogated the effect of G. lucidum on cell proliferation without alteration of G. lucidum-induced attenuation of VEGF expression.

Conclusions: G. lucidum inhibits ovarian cancer by down-regulating the expression of VEGF and up-regulating the downstream Cx43 expression. G. lucidum may be a promising therapeutic agent for the treatment of ovarian cancer.

Show MeSH
Related in: MedlinePlus